Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial February 14, 2022
Axial Therapeutics Raises $37.25 Million in Series C Financing to Advance its Pipeline of Gut-Targeted Small Molecule Drugs for Neurological Diseases and Disorders October 13, 2021
Treating autism through the gut? Axial Therapeutics refuels on its exploration of the gut-brain axis October 13, 2021
